Sung Ji Nam
Stock Analyst at Scotiabank
(2.28)
# 2,705
Out of 5,030 analysts
83
Total ratings
44.93%
Success rate
-1.46%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $65.46 | -8.34% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $61.86 | +21.24% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $209.06 | +31.54% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $538.92 | +9.48% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $95.46 | +30.94% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $22.14 | +80.67% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $6.42 | +523.05% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $7.80 | -23.08% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.90 | +110.53% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.64 | +21.95% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $61.23 | +19.22% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $16.30 | -26.38% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $334.59 | +34.49% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $28.16 | +120.17% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $35.83 | +22.80% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $14.41 | +142.89% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $5.11 | +17.42% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.68 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $65.46
Upside: -8.34%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $61.86
Upside: +21.24%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $209.06
Upside: +31.54%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $538.92
Upside: +9.48%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $95.46
Upside: +30.94%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $22.14
Upside: +80.67%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $6.42
Upside: +523.05%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $7.80
Upside: -23.08%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.90
Upside: +110.53%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.64
Upside: +21.95%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $61.23
Upside: +19.22%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $16.30
Upside: -26.38%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $334.59
Upside: +34.49%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $28.16
Upside: +120.17%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $35.83
Upside: +22.80%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $14.41
Upside: +142.89%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $5.11
Upside: +17.42%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $22.68
Upside: -